Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Malignant Melanoma

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 84 articles: HTML format

Single Articles

May 2020
1. WANG X, Xiong H, Liang D, Chen Z, et al
   The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients.
   BMC Cancer. 2020;20:378.
   PubMed     Abstract available
   
   
   April 2020
2. ALI A, Dumbrava M, Riddell K, Stewart N, et al
   Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial.
   BMC Cancer. 2020;20:342.
   PubMed     Abstract available
   
   
   
3. DAI WF, Beca JM, Croxford R, Isaranawatchai W, et al
   Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada.
   BMC Cancer. 2020;20:304.
   PubMed     Abstract available
   
   
   March 2020
4. LIU F, Hu L, Pei Y, Zheng K, et al
   Long non-coding RNA AFAP1-AS1 accelerates the progression of melanoma by targeting miR-653-5p/RAI14 axis.
   BMC Cancer. 2020;20:258.
   PubMed     Abstract available
   
   
   February 2020
5. HOPKINS AM, Rathod AD, Rowland A, Kichenadasse G, et al
   Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.
   BMC Cancer. 2020;20:157.
   PubMed     Abstract available
   
   
   
6. COROIU A, Moran C, Bergeron C, Drapeau M, et al
   Short and long-term barriers and facilitators of skin self-examination among individuals diagnosed with melanoma.
   BMC Cancer. 2020;20:123.
   PubMed     Abstract available
   
   
   November 2019
7. BOURN J, Rathore K, Donnell R, White W, et al
   Detection of carcinogen-induced bladder cancer by fluorocoxib A.
   BMC Cancer. 2019;19:1152.
   PubMed     Abstract available
   
   
   
8. ZHANG Z, Imani S, Shasaltaneh MD, Hosseinifard H, et al
   The role of vascular mimicry as a biomarker in malignant melanoma: a systematic review and meta-analysis.
   BMC Cancer. 2019;19:1134.
   PubMed     Abstract available
   
   
   
9. CALAPRE L, Warburton L, Millward M, Gray ES, et al
   Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report.
   BMC Cancer. 2019;19:1109.
   PubMed     Abstract available
   
   
   
10. SOARES DE SA BC, de Macedo MP, Torrezan GT, Braga JCT, et al
    BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
    BMC Cancer. 2019;19:1077.
    PubMed     Abstract available
    
    
    October 2019
11. YOSHINO K, Nakayama T, Ito A, Sato E, et al
    Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    BMC Cancer. 2019;19:1019.
    PubMed     Abstract available
    
    
    
12. TANAKA K, Nakamura Y, Mizutani T, Shibata T, et al
    Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma: Japan Clinical Oncology Group study (JCOG1602, J-NAIL study protocol).
    BMC Cancer. 2019;19:1002.
    PubMed     Abstract available
    
    
    
13. STOPPEK AK, Kebir S, Junker A, Keyvani K, et al
    Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.
    BMC Cancer. 2019;19:995.
    PubMed     Abstract available
    
    
    
14. LI L, Zhang S, Li H, Chou H, et al
    FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR.
    BMC Cancer. 2019;19:963.
    PubMed     Abstract available
    
    
    August 2019
15. DOMA V, Karpati S, Raso E, Barbai T, et al
    Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.
    BMC Cancer. 2019;19:853.
    PubMed     Abstract available
    
    
    
16. LAWRANCE S, Bui C, Mahindra V, Arcorace M, et al
    Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
    BMC Cancer. 2019;19:850.
    PubMed     Abstract available
    
    
    
17. LEE J, Lee SJ, Kim K, Kim ST, et al
    Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody.
    BMC Cancer. 2019;19:805.
    PubMed     Abstract available
    
    
    
18. DOMA V, Karpathy S, Raso E, Barbai T, et al
    Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.
    BMC Cancer. 2019;19:786.
    PubMed     Abstract available
    
    
    
19. CASULA M, Paliogiannis P, Ayala F, De Giorgi V, et al
    Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
    BMC Cancer. 2019;19:772.
    PubMed     Abstract available
    
    
    July 2019
20. MATTAINI KR, Sullivan MR, Lau AN, Fiske BP, et al
    Increased PHGDH expression promotes aberrant melanin accumulation.
    BMC Cancer. 2019;19:723.
    PubMed     Abstract available
    
    
    
21. LOKHANDWALA PM, Tseng LH, Rodriguez E, Zheng G, et al
    Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
    BMC Cancer. 2019;19:665.
    PubMed     Abstract available
    
    
    June 2019
22. XU M, Wang X, Pan Y, Zhao X, et al
    Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
    BMC Cancer. 2019;19:599.
    PubMed     Abstract available
    
    
    May 2019
23. VAN BUSSEL MTJ, Beijnen JH, Brandsma D
    Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.
    BMC Cancer. 2019;19:519.
    PubMed     Abstract available
    
    
    
24. MURALI VS, Chang BJ, Fiolka R, Danuser G, et al
    An image-based assay to quantify changes in proliferation and viability upon drug treatment in 3D microenvironments.
    BMC Cancer. 2019;19:502.
    PubMed     Abstract available
    
    
    
25. JONES NM, Yang H, Zhang Q, Morales-Tirado VM, et al
    Natural killer cells and pigment epithelial-derived factor control the infiltrative and nodular growth of hepatic metastases in an Orthotopic murine model of ocular melanoma.
    BMC Cancer. 2019;19:484.
    PubMed     Abstract available
    
    
    
26. JESPERSEN H, Bagge RO, Ullenhag G, Carneiro A, et al
    Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
    BMC Cancer. 2019;19:415.
    PubMed     Abstract available
    
    
    April 2019
27. KLICKS J, Masslo C, Kluth A, Rudolf R, et al
    A novel spheroid-based co-culture model mimics loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced selection of ABCB5-expressing cells.
    BMC Cancer. 2019;19:402.
    PubMed     Abstract available
    
    
    March 2019
28. BLAIR CM, Walsh NM, Littman BH, Marcoux FW, et al
    Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
    BMC Cancer. 2019;19:266.
    PubMed     Abstract available
    
    
    
29. KRUCKEL A, Moreira A, Frohlich W, Schuler G, et al
    Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma.
    BMC Cancer. 2019;19:207.
    PubMed     Abstract available
    
    
    January 2019
30. AN Q, Liu Z
    Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis.
    BMC Cancer. 2019;19:43.
    PubMed     Abstract available
    
    
    
31. AHN MY, Kim BJ, Kim HJ, Jin JM, et al
    Anti-cancer effect of dung beetle glycosaminoglycans on melanoma.
    BMC Cancer. 2019;19:9.
    PubMed     Abstract available
    
    
    December 2018
32. MCQUADE JL, Homsi J, Torres-Cabala CA, Bassett R, et al
    A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.
    BMC Cancer. 2018;18:1274.
    PubMed     Abstract available
    
    
    
33. ROSE AM, Luo R, Radia UK, Kalirai H, et al
    Detection of mutations in SF3B1, EIF1AX and GNAQ in primary orbital melanoma by candidate gene analysis.
    BMC Cancer. 2018;18:1262.
    PubMed     Abstract available
    
    
    
34. TERAS M, Viisileht E, Pahtma-Hall M, Rump A, et al
    Porcine circovirus type 2 ORF3 protein induces apoptosis in melanoma cells.
    BMC Cancer. 2018;18:1237.
    PubMed     Abstract available
    
    
    
35. SEGAOULA Z, Primot A, Lepretre F, Hedan B, et al
    Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology.
    BMC Cancer. 2018;18:1219.
    PubMed     Abstract available
    
    
    November 2018
36. EWENS KG, Lalonde E, Richards-Yutz J, Shields CL, et al
    Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma.
    BMC Cancer. 2018;18:1172.
    PubMed     Abstract available
    
    
    October 2018
37. IIDA Y, Salomon MP, Hata K, Tran K, et al
    Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.
    BMC Cancer. 2018;18:1054.
    PubMed     Abstract available
    
    
    
38. KHONG B, Lawson BO, Ma J, McGovern C, et al
    Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.
    BMC Cancer. 2018;18:1007.
    PubMed     Abstract available
    
    
    
39. SONG X, Guo C, Zheng Y, Wang Y, et al
    Post-transcriptional regulation of cancer/testis antigen MAGEC2 expression by TRIM28 in tumor cells.
    BMC Cancer. 2018;18:971.
    PubMed     Abstract available
    
    
    September 2018
40. VILLAREAL MO, Sato Y, Matsuyama K, Isoda H, et al
    Correction to: Daphnane diterpenes inhibit the metastatic potential of B16F10 murine melanoma cells in vitro and in vivo.
    BMC Cancer. 2018;18:902.
    PubMed     Abstract available
    
    
    
41. RETEL VP, Steuten LMG, Geukes Foppen MH, Mewes JC, et al
    Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.
    BMC Cancer. 2018;18:895.
    PubMed     Abstract available
    
    
    August 2018
42. SARAF RS, Datta A, Sima C, Hua J, et al
    An in-silico study examining the induction of apoptosis by Cryptotanshinone in metastatic melanoma cell lines.
    BMC Cancer. 2018;18:855.
    PubMed     Abstract available
    
    
    
43. VILLAREAL MO, Sato Y, Matsuyama K, Isoda H, et al
    Daphnane diterpenes inhibit the metastatic potential of B16F10 murine melanoma cells in vitro and in vivo.
    BMC Cancer. 2018;18:856.
    PubMed     Abstract available
    
    
    
44. KUCHERLAPATI M
    Examining transcriptional changes to DNA replication and repair factors over uveal melanoma subtypes.
    BMC Cancer. 2018;18:818.
    PubMed     Abstract available
    
    
    July 2018
45. MCEVOY AC, Warburton L, Al-Ogaili Z, Celliers L, et al
    Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.
    BMC Cancer. 2018;18:726.
    PubMed     Abstract available
    
    
    
46. AMINI-ADLE M, Khanafer N, Le-Bouar M, Duru G, et al
    Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.
    BMC Cancer. 2018;18:705.
    PubMed     Abstract available
    
    
    June 2018
47. XIAO J, Egger ME, McMasters KM, Hao H, et al
    Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
    BMC Cancer. 2018;18:675.
    PubMed     Abstract available
    
    
    
48. KHAN MA, Akram T, Sharif M, Shahzad A, et al
    An implementation of normal distribution based segmentation and entropy controlled features selection for skin lesion detection and classification.
    BMC Cancer. 2018;18:638.
    PubMed     Abstract available
    
    
    
49. INOUE K, Tsubamoto H, Isono-Nakata R, Sakata K, et al
    Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report.
    BMC Cancer. 2018;18:630.
    PubMed     Abstract available
    
    
    May 2018
50. GUIDA M, Tommasi S, Strippoli S, Natalicchio MI, et al
    The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
    BMC Cancer. 2018;18:552.
    PubMed     Abstract available
    
    
    
51. MCDONALD MA, Sanghvi P, Bykowski J, Daniels GA, et al
    Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    BMC Cancer. 2018;18:549.
    PubMed     Abstract available
    
    
    
52. SI L, Zhang X, Xu Z, Jiang Q, et al
    Vemurafenib in Chinese patients with BRAF(V600) mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.
    BMC Cancer. 2018;18:520.
    PubMed     Abstract available
    
    
    April 2018
53. VOSOUGHI E, Lee JM, Miller JR, Nosrati M, et al
    Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.
    BMC Cancer. 2018;18:490.
    PubMed     Abstract available
    
    
    
54. LI Y, Zhang J, Liu Y, Zhang B, et al
    MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells.
    BMC Cancer. 2018;18:404.
    PubMed     Abstract available
    
    
    February 2018
55. SOOTICHOTE R, Thuwajit P, Singsuksawat E, Warnnissorn M, et al
    Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
    BMC Cancer. 2018;18:231.
    PubMed     Abstract available
    
    
    
56. BURAZOR I, Aviel-Ronen S, Imazio M, Goitein O, et al
    Metastatic cardiac tumors: from clinical presentation through diagnosis to treatment.
    BMC Cancer. 2018;18:202.
    PubMed     Abstract available
    
    
    
57. MA Q, Shilkrut M, Zhao Z, Li M, et al
    Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data.
    BMC Cancer. 2018;18:145.
    PubMed     Abstract available
    
    
    
58. ZAGER JS, Gastman BR, Leachman S, Gonzalez RC, et al
    Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    BMC Cancer. 2018;18:130.
    PubMed     Abstract available
    
    
    January 2018
59. BUDDEN T, van der Westhuizen A, Bowden NA
    Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.
    BMC Cancer. 2018;18:100.
    PubMed     Abstract available
    
    
    
60. DEPCZYNSKI J, Dobbins T, Armstrong B, Lower T, et al
    Comparison of cancer incidence in Australian farm residents 45 years and over, compared to rural non-farm and urban residents - a data linkage study.
    BMC Cancer. 2018;18:33.
    PubMed     Abstract available
    
    
    
61. KIKULSKA A, Rausch T, Krzywinska E, Pawlak M, et al
    Coordinated expression and genetic polymorphisms in Grainyhead-like genes in human non-melanoma skin cancers.
    BMC Cancer. 2018;18:23.
    PubMed     Abstract available
    
    
    December 2017
62. SONG L, McNeil EM, Ritchie AM, Astell KR, et al
    Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase zeta.
    BMC Cancer. 2017;17:864.
    PubMed     Abstract available
    
    
    
63. KUZBICKI L, Lange D, Stanek-Widera A, Chwirot BW, et al
    Prognostic significance of RBP2-H1 variant of JARID1B in melanoma.
    BMC Cancer. 2017;17:854.
    PubMed     Abstract available
    
    
    November 2017
64. OZAKI Y, Shindoh J, Miura Y, Nakajima H, et al
    Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.
    BMC Cancer. 2017;17:778.
    PubMed     Abstract available
    
    
    
65. CIRILO PDR, de Sousa Andrade LN, Correa BRS, Qiao M, et al
    MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.
    BMC Cancer. 2017;17:750.
    PubMed     Abstract available
    
    
    
66. CHAGANI S, Wang R, Carpenter EL, Lohr CV, et al
    Ablation of epidermal RXRalpha in cooperation with activated CDK4 and oncogenic NRAS generates spontaneous and acute neonatal UVB induced malignant metastatic melanomas.
    BMC Cancer. 2017;17:736.
    PubMed     Abstract available
    
    
    October 2017
67. MIDDLETON MR, Atkins MB, Amos K, Wang PF, et al
    Societal preferences for adjuvant melanoma health states: UK and Australia.
    BMC Cancer. 2017;17:689.
    PubMed     Abstract available
    
    
    September 2017
68. VAN DER HIEL B, Haanen JBAG, Stokkel MPM, Peeper DS, et al
    Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter st
    BMC Cancer. 2017;17:649.
    PubMed     Abstract available
    
    
    August 2017
69. FALKENIUS J, Johansson H, Tuominen R, Frostvik Stolt M, et al
    Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
    BMC Cancer. 2017;17:584.
    PubMed     Abstract available
    
    
    
70. DE SMEDT J, Van Kelst S, Boecxstaens V, Stas M, et al
    Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.
    BMC Cancer. 2017;17:562.
    PubMed     Abstract available
    
    
    
71. HARRER DC, Simon B, Fujii SI, Shimizu K, et al
    RNA-transfection of gamma/delta T cells with a chimeric antigen receptor or an alpha/beta T-cell receptor: a safer alternative to genetically engineered alpha/beta T cells for the immunotherapy of melanoma.
    BMC Cancer. 2017;17:551.
    PubMed     Abstract available
    
    
    
72. HEPPT MV, Siepmann T, Engel J, Schubert-Fritschle G, et al
    Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    BMC Cancer. 2017;17:536.
    PubMed     Abstract available
    
    
    June 2017
73. GAUSTAD JV, Simonsen TG, Andersen LMK, Rofstad EK, et al
    Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts.
    BMC Cancer. 2017;17:411.
    PubMed     Abstract available
    
    
    May 2017
74. LI X, Li Z, Li X, Liu B, et al
    Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell.
    BMC Cancer. 2017;17:357.
    PubMed     Abstract available
    
    
    
75. GAMBICHLER T, Strutzmann S, Tannapfel A, Susok L, et al
    Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
    BMC Cancer. 2017;17:327.
    PubMed     Abstract available
    
    
    March 2017
76. BHANGOO MS, Zhou JY, Ali SM, Madison R, et al
    Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report.
    BMC Cancer. 2017;17:197.
    PubMed     Abstract available
    
    
    February 2017
77. REIMAN A, Kikuchi H, Scocchia D, Smith P, et al
    Validation of an NGS mutation detection panel for melanoma.
    BMC Cancer. 2017;17:150.
    PubMed     Abstract available
    
    
    January 2017
78. MERZOUG-LARABI M, Spasojevic C, Eymard M, Hugonin C, et al
    Protein kinase C inhibitor Go6976 but not Go6983 induces the reversion of E- to N-cadherin switch and metastatic phenotype in melanoma: identification of the role of protein kinase D1.
    BMC Cancer. 2017;17:12.
    PubMed     Abstract available
    
    
    
79. O'SHEA SJ, Rogers Z, Warburton F, Ramirez AJ, et al
    Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study.
    BMC Cancer. 2017;17:5.
    PubMed     Abstract available
    
    
    December 2016
80. CAISOVA V, Vieru A, Kumzakova Z, Glaserova S, et al
    Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.
    BMC Cancer. 2016;16:940.
    PubMed     Abstract available
    
    
    
81. SCHOFFER O, Schulein S, Arand G, Arnholdt H, et al
    Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011.
    BMC Cancer. 2016;16:936.
    PubMed     Abstract available
    
    
    November 2016
82. SCHIROSI L, Strippoli S, Gaudio F, Graziano G, et al
    Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
    BMC Cancer. 2016;16:905.
    PubMed     Abstract available
    
    
    
83. CHIEN CH, Lee MJ, Liou HC, Liou HH, et al
    Growth hormone is increased in the lungs and enhances experimental lung metastasis of melanoma in DJ-1 KO mice.
    BMC Cancer. 2016;16:871.
    PubMed     Abstract available
    
    
    January 2016
84. GRASSO C, Anaka M, Hofmann O, Sompallae R, et al
    Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations.
    BMC Cancer. 2016;16:726.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: